Zusammenfassung. Fragestellung: Pädagogische und medizinische Institutionen betreuen Kinder und Jugendliche, um Aufsicht, Beschulung, Erziehung, Therapie und Schutz sicherzustellen. Gleichwohl sind Kinder in institutioneller Betreuung potenziellen Gefährdungsmomenten bezüglich Misshandlung und Missbrauch ausgesetzt. Methodik: Im Rahmen der Etablierung des Schutzkonzeptes der Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie am Universitätsklinikum Würzburg wurde eine retrospektive Patientenbefragung durchgeführt. Das Untersuchungskollektiv bildeten alle ehemaligen stationären Patientinnen und Patienten der Jahre 2006 und 2007, die zum Katamnesezeitpunkt volljährig waren. Die Befragung erfolgte postalisch. Der Fragebogen umfasste neben Items zum Kontext von Gewalterfahrungen etablierte Skalen zur Erfassung von Behandlungszufriedenheit und Lebensqualität (FBB-K, WHO-BREF). Ergebnisse: Von 568 ehemaligen Patientinnen und Patienten gaben 87 (15.3 %) eine gültige Rückantwort (59 weiblich, durchschnittliches Alter zum Befragungszeitpunkt: 24.5 Jahre). 35 ehemalige Patientinnen und Patienten (40.2 % der Teilnehmenden) gaben an, Gewalt während der stationären Behandlung erlebt ( n = 26) oder erlebt und ausgeübt ( n = 7) oder ausschließlich ausgeübt ( n = 2) zu haben. Gewalterfahrungen beinhalteten in den meisten Fällen emotionale Gewalt (34.5 %), aber auch körperliche (5.7 %) und sexuelle Gewalt (10.3 %). Schlussfolgerung: Es zeigte sich ein signifikanter Zusammenhang zwischen Gewalterfahrungen einerseits sowie retrospektiver Behandlungszufriedenheit und aktueller Lebensqualität andererseits. Die Ergebnisse der Befragung unterstreichen die Bedeutung der Etablierung von Schutzkonzepten in Kliniken und anderen Institutionen.

Handedness has been studied for association with language-related disorders because of its link with language hemispheric dominance. No clear pattern has emerged, possibly because of small samples, publication bias, and heterogeneous criteria across studies. Non-right-handedness (NRH) frequency was assessed in N = 2503 cases with reading and/or language impairment and N = 4316 sex-matched controls identified from 10 distinct cohorts (age range 6-19 years old; European ethnicity) using a priori set criteria. A meta-analysis (Ncases  = 1994) showed elevated NRH % in individuals with language/reading impairment compared with controls (OR = 1.21, CI = 1.06-1.39, p = .01). The association between reading/language impairments and NRH could result from shared pathways underlying brain lateralization, handedness, and cognitive functions.

Experiences of Violence During Inpatient Child and Adolescent Psychiatric Treatment: An Explorative Study with Implications for Child Protection Abstract. Objective: Educational and medical institutions care for children and adolescents by providing supervision, schooling, education, therapy, and protection. Nevertheless, children in institutional care are exposed to potential danger through maltreatment and abuse. Method: As part of the establishment of the protection concept at the University Hospital for Child and Adolescent Psychiatry in Würzburg, a retrospective patient survey was conducted. The study population consisted of former inpatient clients from 2006 and 2007, who at the time of the catamnesis were of legal age. The survey was conducted by mail. In addition to items on their experiences of violence, the questionnaire included established scales to assess treatment satisfaction and quality of life (FBB-K, WHO-BREF). Results: Of 568 former patients, 87 (15.3 %) provided valid responses (59 female, mean age at the time of the survey: 24.5 years): 35 former patients (40.2 % of the participants) reported experiences of violence during their inpatient treatment (26 victims only, 7 experiences as victims and perpetrators, and 2 perpetrators only). Experiences as victims mainly included emotional violence (34.5 %), but also physical (5.7 %) and sexual violence (10.3 %). Conclusion: We found a significant correlation between experiences of violence, on the one hand, and retrospective treatment satisfaction and current quality of life, on the other hand. The results of the survey underline the importance of establishing protection concepts in clinics and other institutions.

Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose-concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20-60 ng/ml) is applicable for minors. In the 64 patients (aged 11-18 years) included, a positive correlation between daily dose and the active moiety (RISam) concentration was found (r(s) = 0.49, p = 0.001) with variation in dose explaining 24% (r(s)(2) = 0.240) of the variability in serum concentrations. While the RISam concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RISam concentrations than patients without (p = 0.05). Considering EPS, the upper threshold of the therapeutic range of RISam was determined to be 33 ng/ml. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions.

Worldwide, the majority of people prefer using the right hand for most motor tasks, including writing. Because of the link between handedness and language hemispheric dominance, handedness has been studied for association with language-related disorders. No clear pattern has emerged from these studies, and inconsistencies have been attributed to small sample sizes, publication bias, and heterogeneous criteria for the definition of handedness and disorders.Here, we assessed the frequency of non-right handedness (NRH) in 10 distinct cohorts not analysed before in this context. We identified N = 2,499 cases with reading and/or language impairment and N = 4,428 unique controls on the basis of a priori defined criteria. Overall, NRH was more frequent and more variable in the cases (8-24%) than in the controls (8-16%). Meta-analysis in the eight cohorts that met the inclusion criteria showed an increase of NRH in individuals with language/reading impairment compared to controls (OR = 1.21, CI = 1.06 - 1.37, p = 0.009). No moderator effects were detected for type of cohort (epidemiological versus clinical) and type of impairment (language versus reading). Our results support a genuine but modest association between NRH and reading and language impairments, suggesting shared biological pathways underlying brain lateralization, handedness, and cognitive functions.

Obsessive-compulsive disorder (OCD) causes severe distress and is therefore counted by the World Health Organisation (WHO) as one of the 10 most impairing illnesses. There is evidence for a strong genetic underpinning especially in early onset OCD (eoOCD). Though several genes involved in neurotransmission have been reported as candidates, there is still a need to identify new pathways. In this study, we focussed on genetic variants of the Neuropeptide Y (NPY) system. NPY is one of the most abundant neuropeptides in the human brain with emerging evidence of capacity to modulate stress response, which is of high relevance in OCD. We focussed on tag-SNPs of NPY and its receptor gene NPY1R in a family-based approach. The sample comprised 86 patients (children and adolescents) with eoOCD with both their biological parents. However, this first study on genetic variants of the NPY-system could not confirm the association between the investigated SNPs and eoOCD. Based on the small sample size results have to be interpreted as preliminary and should be replicated in larger samples. However, also in an additional GWAS analysis in a large sample, we could not observe an associations between NPY and OCD. Overall, these preliminary results point to a minor role of NPY on the stress response of OCD.

The original article was missing a statement regarding a shared first authorship. The authors Julia M. Geissler and Timo D. Vloet contributed equally to the manuscript.

IMPORTANCE Knowledge about the long-term effects of multimodal treatment in adult attention-deficit/hyperactivity disorder (ADHD) is much needed. OBJECTIVE To evaluate the long-term efficacy of multimodal treatment for adult ADHD. DESIGN, SETTING, AND PARTICIPANTS This observer-masked, 1.5-year follow-up of the Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS), a prospective, multicenter randomized clinical trial, compared cognitive behavioral group psychotherapy (GPT) with individual clinical management (CM) and methylphenidate (MPH) with placebo (2 x 2 factorial design). Recruitment started January 2007 and ended August 2010, and treatments were finalized in August 2011 with follow-up through March 2013. Overall, 433 adults with ADHD participated in the trial, and 256 (59.1%) participated in the follow-up assessment. Analysis began in November 2013 and was completed in February 2018. INTERVENTIONS After 1-year treatment with GPT or CM and MPH or placebo, no further treatment restrictions were imposed. MAIN OUTCOMES AND MEASURES The primary outcome was change in the observer-masked ADHD Index of Conners Adult ADHD Rating Scale score from baseline to follow-up. Secondary outcomes included further ADHD rating scale scores, observer-masked ratings of the Clinical Global Impression scale, and self-ratings of depression on the Beck Depression Inventory. RESULTS At follow-up, 256 of 433 randomized patients (baseline measured in 419 individuals) participated. Of the 256 patients participating in follow-up, the observer-masked ADHD Index of Conners Adult ADHD Rating Scale score was assessed for 251; the mean (SD) baseline age was 36.3 (10.1) years; 125 patients (49.8%) were men; and the sample was well-balanced with respect to prior randomization (GPT and MPH: 64 of 107; GPT and placebo: 67 of 109; CM and MPH: 70 of 110; and CM and placebo: 55 of 107). At baseline, the all-group mean ADHD Index of Conners Adult ADHD Rating Scale score was 20.6, which improved to adjusted means of 14.2 for the GPT arm and 14.7 for the CM arm at follow-up with no significant difference between groups (difference, -0.5; 95% CI, -1.9 to 0.9; P=.48). The adjusted mean decreased to 13.8 for the MPH arm and 15.2 for the placebo arm (difference, -1.4; 95% CI, -2.8 to -0.1; P=.04). As in the core study, MPH was associated with a larger reduction in symptoms than placebo at follow-up. These results remained unchanged when accounting for MPH intake at follow-up. Compared with participants in the CM arm, patients who participated in group psychotherapy were associated with less severe symptoms as measured by the self-reported ADHD Symptoms Total Score according to the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) of Conners Adult ADHD Rating Scale (AMD, -2.1; 95% CI, -4.2 to -0.1; P=.04) and in the subscale of reducing pure hyperactive symptoms, measured via the Diagnostic Checklist for the diagnosis of ADHD in adults (AMD, -1.3; 95% CI, -2.8 to 0.1; P=.08). Regarding the Clinical Global Impression scale assessment of effectiveness, the difference between GPT and CM remained significant at follow-up (odds ratio, 1.63; 95% CI, 1.03-2.59; P=.04). No differences were found for any comparison concerning depression as measured with the Beck Depression Inventory. CONCLUSIONS AND RELEVANCE Results from COMPAS demonstrate a maintained improvement in ADHD symptoms for adults 1.5 years after the end of a 52-week controlled multimodal treatment period. The results indicate that MPH treatment combined with GPT or CM provides a benefit lasting 1.5 years. Confirming the results of the core study, GPT was not associated with better results regarding the primary outcome compared with CM. TRIAL REGISTRATION isrctn.org Identifier: ISRCTN54096201

Multimodal treatment of children with ADHD often includes parent–child training (PCT). However, due to the high heritability, parents of children with ADHD are frequently also affected by the disorder, which is likely to constitute a significant barrier to successful treatment of the child. This secondary analysis of our randomized controlled multicentre AIMAC trial (ADHD in mothers and children) investigates whether children’s outcomes following parent–child training in combination with maternal ADHD treatment depend on maternal symptom improvement. In a first step focusing on treatment of maternal ADHD, 144 mothers of mother–child dyads were randomized to multimodal ADHD treatment (group psychotherapy plus methylphenidate) or clinical management (mainly supportive counselling). After 12 weeks (T2), a 12-week PCT program (T2–T3) for all mother–child dyads was added to treat children’s ADHD. Maternal symptomatology (CAARS-O:L; SCL-90-R) and children’s externalizing symptoms (ADHD-ODD Scale, SDQ) were repeatedly assessed (T1 = baseline, T2, T3). Effects of changes in maternal symptomatology (T1–T2) on the change in children’s symptom scores (T1–T3) were analysed using a general linear model, controlling for baseline scores, study centre, and maternal treatment group. 125 mother–child dyads were analysed. Mothers showed significant improvements in ADHD symptoms and overall psychopathology [CAARS-O:L ADHD index: mean − 3.54, SE 0.74 p < 0.0001; SCL-90-R Global Severity (GS): mean − 11.03, SE 3.90, p = 0.0056]. Although children’s externalizing symptoms improved significantly (ADHD-ODD Scale: mean − 4.46, SE 0.58, p < 0.0001), maternal improvement had no effect on children’s outcomes after Bonferroni–Holm correction for multiple testing. The findings do not support our hypothesis that children’s outcomes following PCT for ADHD depend on maternal symptom improvements.

Zusammenfassung In der gesundheitlichen Versorgung gilt es, chronisch Kranke in ihren Fähigkeiten zu stärken, sich und ihre Erkrankung erfolgreich zu bewältigen bzw. zu managen. Versorgungs- und Case-Management unterstützen diese Prozesse und erfordern von den beteiligten Gesundheitsberufen zunehmend kommunikative und pädagogische Kompetenzen.

The efficacy of parent-child training (PCT) regarding child symptoms may be reduced if the mother has attention-deficit/hyperactivity disorder (ADHD). The AIMAC study (ADHD in Mothers and Children) aimed to compensate for the deteriorating effect of parental psychopathology by treating the mother (Step 1) before the beginning of PCT (Step 2). This secondary analysis was particularly concerned with the additional effect of the Step 2 PCT on child symptoms after the Step 1 treatment.

OBJECTIVEWe examined predictors and moderators of treatment outcome in mothers and children diagnosed with ADHD in a large multicentre RCT.METHODIn total, 144 mother-child dyads with ADHD were randomly assigned to either a maternal ADHD treatment (group psychotherapy and open methylphenidate medication, TG) or to a control treatment (individual counselling without psycho- or pharmacotherapy, CG). After maternal ADHD treatment, parent-child training (PCT) for all mother-child dyads was added. The final analysis set was based on 123 dyads with completed primary outcome assessments (TG: n = 67, CG: n = 56). The primary outcome was the change in each child's externalizing symptoms. Multiple linear regression analyses were performed.RESULTSThe severity of the child's externalizing problem behaviour in the family at baseline predicted more externalizing symptoms in the child after PCT, independent of maternal treatment. When mothers had a comorbid depression, TG children showed more externalizing symptoms after PCT than CG children of depressive mothers. No differences between the treatment arms were seen in the mothers without comorbid depression.CONCLUSIONSSeverely impaired mothers with ADHD and depressive disorder are likely to need additional disorder-specific treatment for their comorbid psychiatric disorders to effectively transfer the contents of the PCT to the home situation (CCTISRCTN73911400).

Medikamentöse Behandlung in der Kinder- und Jugendpsychiatrie in Deutschland zwischen ethischen sowie sozial- und haftungsrechtlichen KonfliktenManfred Gerlach and Andreas WarnkeManfred GerlachZentrum für Psychische Gesundheit, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum WürzburgArbeitsgruppe „Kinder- und jugendpsychiatrische Pharmakologie“ der AGNPSearch for more papers by this author and Andreas WarnkeZentrum für Psychische Gesundheit, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum WürzburgSearch for more papers by this authorPublished Online:July 18, 2016https://doi.org/10.1024/1422-4917/a000430PDFView Full Text ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit SectionsMoreLiteraturBanaschewski, T., Gerlach, M., Becker, K., Holtmann, M., Döpfner, M. & Romanos, M. (2016). Trust, but verify. The errors and misinterpretations in the Cochrane analysis by O. J. Strorebo and colleagues on the efficacy and safety of methylphenidate for the treatment of children and adolescents with ADHD. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, im Druck. First citation in articleGoogle ScholarEgberts, K., Karwautz, A., Plener, P. L., Mehler-Wex, C., Kölch, M., Stingl, J., Dang, S.-Y., Taurines, R., Romanos, M. & Gerlach, M. (2015). Pharmakovigilanz in der Kinder- und Jugendpsychiatrie. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 43, 21–28. First citation in articleLink, Google ScholarEuropean Medicines Agency (2013). Committee for Medicinal Products for Human use (CHMP). Successes of the paediatric regulation after 5 years – August 2007–December 2012. 6 June; (http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500143984.pdf). First citation in articleGoogle ScholarFegert, J. M., Kölch, M., Lippert, H. D. & Oehler, K.-U. und die Mitglieder der Kommission Entwicklungspsychopharmakologie (2008). Stellungnahme der Kommission Entwicklungspharmakologie zum Off-label-Use. Forum für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, 2, 99–109. First citation in articleGoogle ScholarFranke, C., Fegert, J. M., Krüger, U. & Kölch, M. (2016). Verordnungshäufigkeiten von Psychopharmaka bei Kindern und Jugendlichen mit psychischen Erkrankungen in Deutschland. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, im Druck. First citation in articleLink, Google ScholarHarrison, J. N., Cluxton-Keller, F. & Gross, D. (2013). Antipsychotic medication prescribing trends in children and adolescents. Journal of Pediatric Health Care, 26, . First citation in articleGoogle ScholarKölch, M. (2016). Rechtliche und ethische Fragen im klinischen Alltag. In M. Gerlach, C. Mehler-Wex, S. Walitza, A. Warnke & Ch. Wewetzer (Hrsg.), Neuro-Psychopharmaka im Kindes- und Jugendalter: Grundlagen und Therapie (3. Auflage, S. 81–90). Wien: Springer, im Druck. First citation in articleCrossref, Google ScholarKoelch, M. & Fegert, J. M. (2010). Ethics in child and adolescent psychiatric care: an international perspective. International Review Psychiatry, 22, . First citation in articleCrossref Medline, Google ScholarLehmkuhl, G & Schubert, I. (2014). Psychotropic medication in children and adolescents. Deutsches Ärzteblatt International, 111, 23–24. First citation in articleMedline, Google ScholarNational Commission for the Protection of Human Subjects of Biomedical and Beavioral Research (1979). The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research. U. S. Department of Health, Education, and Welfare. http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html. First citation in articleGoogle ScholarPersico, A. M., Arango, C., Buitelaar, J. K., Correll, C. U., Glennon, J. C., Hoekstra, P. J., Moreno, C., Vitiello, B., Vorstman, J. & Zuddas, A., the European Child and Adolescent Clinical Psychopharmacology Network (2015). Unmet needs in paediatric psychopharmacology: present scenario and future perspectives. European Neuropsychopharmacology, 25, . First citation in articleCrossref Medline, Google ScholarPringsheim, T., Doja, A., Gorman, D., McKinlay, D., Day, L., Billinghurst, L., Carroll, A., Dion, Y., Liscombe, S., Steeves, T. & Sandor, P. (2012). Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. The Canadian Journal of Psychiatry, 57, . First citation in articleGoogle ScholarRoessner, V. & Rothenberger, A. (2016). Tic-Störungen. In M. Gerlach, C. Mehler-Wex, S. Walitza, A. Warnke & Ch. Wewetzer (Hrsg.), Neuro-Psychopharmaka im Kindes- und Jugendalter: Grundlagen und Therapie (3. Auflage, S. 599–610). Wien: Springer, im Druck. First citation in articleCrossref, Google ScholarSchmäl, C., Becker, K., Berg, R., Brünger, M., Lehmkuhl, G., Oehler, K. U., Ruppert, T., Staudter, C., Trott, G. E. & Dittmann, R. W. (2014). Pediatric psychopharmacological research in the past EU regulation 1901/2006 era. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 42, . First citation in articleLink, Google ScholarWarnke, A., Fegert, J., Wewetzer, C. & Remschmidt, H. (2008). Ethische Fragen in der Kinder- und Jugendpsychiatrie und Psychotherapie. In B. Herpertz-Dahlmann, F. Resch, M. Schulte-Markwort & A. Warnke (Hrsg.), Entwicklungspsychiatrie. Biopsychologische Grundlagen und die Entwicklung psychischer Störungen. (2. Auflage. S. 471–486). Stuttgart: Schattauer. First citation in articleGoogle ScholarWartensleben, H. (2002). „Off-label-use“. Nutzen der Dopamin-Agonisten reicht über die zugelassene Indikation hinaus. 8. Hamburger Parkinsongespräch, 6. Dezember 2002, Hamburg (Beilage in „Der Nervenarzt“ Band 74, März 2003, S. 7–8). First citation in articleGoogle ScholarFiguresReferencesRelatedDetailsCited byDas pharmakologische Management kinder- und jugendpsychiatrischer Notfälle Evidenz und QualitätssicherungTimo D. Vloet, Stefanie Fekete, Manfred Gerlach, and Marcel Romanos14 October 2021 | Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, Vol. 50, No. 4Psychopharmakologieforschung in der Kinder- und Jugend- psychiatrie – Entwicklungen, Herausforderungen, Perspektiven Psychopharmacology research in child and adolescent psychiatry – Developments, challenges, perspectivesRalf W. Dittmann and Aribert Rothenberger8 November 2019 | Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, Vol. 47, No. 6Polypharmazie in der Anwendung von Psychopharmaka in der deutschen Kinder- und Jugendpsychiatrie – häufiger Regel als AusnahmeTimo D. Vloet, Karin Egberts, Regina Taurines, Christoph Wewetzer, Claudia Mehler-Wex, Paul L. Plener, Marcel Romanos, and Manfred Gerlach13 November 2018 | Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, Vol. 47, No. 3Mitteilungen Die psychopharmakologische Off-label-Verordnung in der Behandlung von Kindern und Jugendlichen mit psychischen StörungenKlaus-U. Oehler, Marcel Romanos, Oya Uzelli-Schwarz, Rainer Dieffenbach, Gunter Vulturius, Martin Holtmann, and Christoph Wewetzer18 July 2016 | Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, Vol. 44, No. 4 Volume 44Issue 4Juli 2016ISSN: 1422-4917eISSN: 1664-2880 Published online18. Juli 2016 InformationZeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie (2016), 44, pp. 249-255 https://doi.org/10.1024/1422-4917/a000430.© 2016Hogrefe AGPDF download